Literature DB >> 28341736

Molecular landscape of acute promyelocytic leukemia at diagnosis and relapse.

Annette Fasan1, Claudia Haferlach2, Karolina Perglerovà3, Wolfgang Kern2, Torsten Haferlach2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28341736      PMCID： PMC5451348          DOI： 10.3324/haematol.2016.162206

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  12 in total

1.  Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment.

Authors:  Emi Goto; Akihiro Tomita; Fumihiko Hayakawa; Akihide Atsumi; Hitoshi Kiyoi; Tomoki Naoe
Journal:  Blood       Date:  2011-05-25       Impact factor: 22.113

2.  Altered ligand binding and transcriptional regulation by mutations in the PML/RARalpha ligand-binding domain arising in retinoic acid-resistant patients with acute promyelocytic leukemia.

Authors:  S Côté; D Zhou; A Bianchini; C Nervi; R E Gallagher; W H Miller
Journal:  Blood       Date:  2000-11-01       Impact factor: 22.113

3.  Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): a retrospective study from the European APL Group.

Authors:  C Callens; S Chevret; J-M Cayuela; B Cassinat; E Raffoux; S de Botton; X Thomas; A Guerci; N Fegueux; A Pigneux; A-M Stoppa; T Lamy; F Rigal-Huguet; A Vekhoff; S Meyer-Monard; A Ferrand; M Sanz; C Chomienne; P Fenaux; H Dombret
Journal:  Leukemia       Date:  2005-07       Impact factor: 11.528

Review 4.  Understanding the molecular pathogenesis of acute promyelocytic leukemia.

Authors:  Francesco Lo-Coco; Syed Khizer Hasan
Journal:  Best Pract Res Clin Haematol       Date:  2014-04-13       Impact factor: 3.020

Review 5.  Acute promyelocytic leukaemia: novel insights into the mechanisms of cure.

Authors:  Hugues de Thé; Zhu Chen
Journal:  Nat Rev Cancer       Date:  2010-10-22       Impact factor: 60.716

6.  Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups.

Authors:  M A Sanz; F Lo Coco; G Martín; G Avvisati; C Rayón; T Barbui; J Díaz-Mediavilla; G Fioritoni; J D González; V Liso; J Esteve; F Ferrara; P Bolufer; C Bernasconi; M Gonzalez; F Rodeghiero; D Colomer; M C Petti; J M Ribera; F Mandelli
Journal:  Blood       Date:  2000-08-15       Impact factor: 22.113

7.  Frequent mutations in the ligand-binding domain of PML-RARalpha after multiple relapses of acute promyelocytic leukemia: analysis for functional relationship to response to all-trans retinoic acid and histone deacetylase inhibitors in vitro and in vivo.

Authors:  Da-Cheng Zhou; Soon H Kim; Wei Ding; Cynthia Schultz; Raymond P Warrell; Robert E Gallagher
Journal:  Blood       Date:  2002-02-15       Impact factor: 22.113

8.  Mutations in the E-domain of RAR portion of the PML/RAR chimeric gene may confer clinical resistance to all-trans retinoic acid in acute promyelocytic leukemia.

Authors:  M Imaizumi; H Suzuki; M Yoshinari; A Sato; T Saito; A Sugawara; S Tsuchiya; Y Hatae; T Fujimoto; A Kakizuka; T Konno; K Iinuma
Journal:  Blood       Date:  1998-07-15       Impact factor: 22.113

9.  Emerging new approaches for the treatment of acute promyelocytic leukemia.

Authors:  Jae Park; Joseph G Jurcic; Todd Rosenblat; Martin S Tallman
Journal:  Ther Adv Hematol       Date:  2011-10

10.  Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia.

Authors:  V Madan; P Shyamsunder; L Han; A Mayakonda; Y Nagata; J Sundaresan; D Kanojia; K Yoshida; S Ganesan; N Hattori; N Fulton; K-T Tan; T Alpermann; M-C Kuo; S Rostami; J Matthews; M Sanada; L-Z Liu; Y Shiraishi; S Miyano; E Chendamarai; H-A Hou; G Malnassy; T Ma; M Garg; L-W Ding; Q-Y Sun; W Chien; T Ikezoe; M Lill; A Biondi; R A Larson; B L Powell; M Lübbert; W J Chng; H-F Tien; M Heuser; A Ganser; M Koren-Michowitz; S M Kornblau; H M Kantarjian; D Nowak; W-K Hofmann; H Yang; W Stock; A Ghavamzadeh; K Alimoghaddam; T Haferlach; S Ogawa; L-Y Shih; V Mathews; H P Koeffler
Journal:  Leukemia       Date:  2016-04-11       Impact factor: 11.528
View more
  11 in total

Review 1.  Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet.

Authors:  Miguel A Sanz; Pierre Fenaux; Martin S Tallman; Elihu H Estey; Bob Löwenberg; Tomoki Naoe; Eva Lengfelder; Hartmut Döhner; Alan K Burnett; Sai-Juan Chen; Vikram Mathews; Harry Iland; Eduardo Rego; Hagop Kantarjian; Lionel Adès; Giuseppe Avvisati; Pau Montesinos; Uwe Platzbecker; Farhad Ravandi; Nigel H Russell; Francesco Lo-Coco
Journal:  Blood       Date:  2019-02-25       Impact factor: 22.113

Review 2.  Acute promyelocytic leukemia (APL): remaining challenges towards a cure for all.

Authors:  Maximilian Stahl; Martin S Tallman
Journal:  Leuk Lymphoma       Date:  2019-12-16

3.  [Clinical and genetic characteristics of patients with newly diagnosed acute promyelocytic leukemia: a single-center retrospective of 790 cases].

Authors:  M Z Yang; L Li; H Wei; B C Liu; K Q Liu; D P Li; L Zhang; R C Yang; Y C Mi; J X Wang; Y Wang
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2022-04-14

4.  Gene mutations in acute promyelocytic leukemia early death in patients treated with arsenic trioxide alone.

Authors:  Xiaotong Chen; Shengjin Fan; Yanqiu Zhao; Jin Zhou
Journal:  Clin Transl Oncol       Date:  2021-05-03       Impact factor: 3.405

Review 5.  Current views on the genetic landscape and management of variant acute promyelocytic leukemia.

Authors:  Xiang Zhang; Jiewen Sun; Wenjuan Yu; Jie Jin
Journal:  Biomark Res       Date:  2021-05-06

6.  Pediatric Acute Promyelocytic Leukemia: Epidemiology, Molecular Features, and Importance of GST-Theta 1 in Chemotherapy Response and Outcome.

Authors:  Francianne G Andrade; Suellen V M Feliciano; Ingrid Sardou-Cezar; Gisele D Brisson; Filipe V Dos Santos-Bueno; Danielle T Vianna; Luísa V C Marques; Eugênia Terra-Granado; Ilana Zalcberg; Marceli de O Santos; Juliana T Costa; Elda P Noronha; Luiz C S Thuler; Joseph L Wiemels; Maria S Pombo-de-Oliveira
Journal:  Front Oncol       Date:  2021-03-19       Impact factor: 6.244

7.  [Acute promyelocytic leukemia with PML cryptic breakpoint t (15; 17) (q22; q21) negative: a case report and literatures review].

Authors:  C Y Wu; Y L Li; X Y Dong; L Zhang; B J Shang; W Cheng; Z F Huang; Z M Zhu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2021-01-14

8.  Microfluidic-Based Detection of AML-Specific Biomarkers Using the Example of Promyelocyte Leukemia.

Authors:  Benedikt Emde; Heike Kreher; Nicole Bäumer; Sebastian Bäumer; Dominique Bouwes; Lara Tickenbrock
Journal:  Int J Mol Sci       Date:  2020-11-25       Impact factor: 5.923

9.  Mutational profile of ZBTB16-RARA-positive acute myeloid leukemia.

Authors:  Emiliano Fabiani; Laura Cicconi; Anna Maria Nardozza; Antonio Cristiano; Marianna Rossi; Tiziana Ottone; Giulia Falconi; Mariadomenica Divona; Anna Maria Testi; Ombretta Annibali; Roberto Castelli; Vladimir Lazarevic; Eduardo Rego; Pau Montesinos; Jordi Esteve; Adriano Venditti; Matteo Della Porta; William Arcese; Francesco Lo-Coco; Maria Teresa Voso
Journal:  Cancer Med       Date:  2021-05-27       Impact factor: 4.452

10.  Alkaloid-based regimen is beneficial for acute myeloid leukemia resembling acute promyelocytic leukemia with NUP98/RARG fusion and RUNX1 mutation: A case report.

Authors:  Wei Wei; Qiuju Liu; Fei Song; He Cao; Mengmeng Liu; Yan Jiang; Yanchun Li; Sujun Gao
Journal:  Medicine (Baltimore)       Date:  2020-10-02       Impact factor: 1.817
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.